The invention relates to parasites, and to methods for purifying a metabolically active obligate parasite of vertebrates and arthropods. The invention is especially concerned with methods of purifying Plasmodium and Theileria parasites, such as P. falciparum and T. parva, and highly motile parasite forms thereof, called sporozoites. The invention also relates to obligate parasites of vertebrates and arthropods purified by the methods of the invention and their use thereof.

The invention relates to parasites, and to methods for purifying a metabolically active obligate parasite of vertebrates and arthropods. The invention is especially concerned with methods of purifying Plasmodium and Theileria parasites, such as P. falciparum and T. parva, and highly motile parasite forms thereof, called sporozoites. The invention also relates to obligate parasites of vertebrates and arthropods purified by the methods of the invention and their use thereof.

Provided herein are eukaryotic microorganisms having a simple lipid profile comprising long chain fatty acids (LCFAs). Also provided are compositions and cultures comprising the eukaryotic microorganisms as well as methods of using the eukaryotic microorganisms.

Provided herein are eukaryotic microorganisms having a simple lipid profile comprising long chain fatty acids (LCFAs). Also provided are compositions and cultures comprising the eukaryotic microorganisms as well as methods of using the eukaryotic microorganisms.

A microorganism screening system includes a container configured to store a liquid containing microorganism particles and a liquid medium, and a microorganism separation device. The microorganism separation device includes a hydrodynamic separation device and a liquid feeding unit configured to supply the liquid from the container to the hydrodynamic separation device. The hydrodynamic separation device includes a curved flow channel having a rectangular cross-section, and is configured to separate the liquid into a first segment containing relatively large microorganism particles and a second segment containing relatively small microorganism particles through use of a vortex flow generated in the liquid flowing through the curved flow channel. Screening for microorganisms can be performed efficiently.

According to the invention, it has been found that when the amount of sulfate used in the culturing of PUFAs-producing cells is selected such that the sulfate concentration in the last phase of fermentation is always above zero, but at the same time always below the saturation limit of the cells, a biomass is obtained which has an increased proportion by mass of polyunsaturated fatty acids (PUFAs) in the final product, the process having at the same time a high product/substrate yield and space/time yield.

According to the invention, it has been found that when the amount of sulfate used in the culturing of PUFAs-producing cells is selected such that the sulfate concentration in the last phase of fermentation is always above zero, but at the same time always below the saturation limit of the cells, a biomass is obtained which has an increased proportion by mass of polyunsaturated fatty acids (PUFAs) in the final product, the process having at the same time a high product/substrate yield and space/time yield.

The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.

The present disclosure provides mutant parasites, in particular protozoan parasites comprising a mutation of the trehalose-6-phosphate synthase/6-phosphate phosphatase (TPS/TPP)-like gene of Toxoplasma gondii (herein referred to as ‘Toxoplasma’) or a homologue thereof as well as vaccines comprising same.

The present disclosure provides mutant parasites, in particular protozoan parasites comprising a mutation of the trehalose-6-phosphate synthase/6-phosphate phosphatase (TPS/TPP)-like gene of Toxoplasma gondii (herein referred to as ‘Toxoplasma’) or a homologue thereof as well as vaccines comprising same.